Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC

Lead investigator Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.